

Transfer of Growth Factor Receptor mRNA Via Exosomes Unravels the Regenerative Effect of Mesenchymal Stem Cells

Susanna Tomasoni,¹ Lorena Longaretti,¹ Cinzia Rota,¹ Marina Morigi,¹ Sara Conti,¹ Elisa Gotti,² Chiara Capelli,² Martino Introna,² Giuseppe Remuzzi,^{1,3} and Ariela Benigni¹

Bone marrow–mesenchymal stem cells (BM-MSc) ameliorate renal dysfunction and repair tubular damage of acute kidney injury by locally releasing growth factors, including the insulin-like growth factor-1 (IGF-1). The restricted homing of BM-MSc at the site of injury led us to investigate a possible gene-based communication mechanism between BM-MSc and tubular cells. Human BM-MSc (hBM-MSc) released microparticles and exosomes (Exo) enriched in mRNAs. A selected pattern of transcripts was detected in Exo versus parental cells. Exo expressed the IGF-1 receptor (IGF-1R), but not IGF-1 mRNA, while hBM-MSc contained both mRNAs. R- cells lacking IGF-1R exposed to hBM-MSc-derived Exo acquired the human IGF-1R transcript that was translated in the corresponding protein. Transfer of IGF-1R mRNA from Exo to cisplatin-damaged proximal tubular cells (proximal tubular epithelial cell [PTEC]) increased PTEC proliferation. Coincubation of damaged PTEC with Exo and soluble IGF-1 further enhanced cell proliferation. These findings suggest that horizontal transfer of the mRNA for IGF-1R to tubular cells through Exo potentiates tubular cell sensitivity to locally produced IGF-1 providing a new mechanism underlying the powerful renoprotection of few BM-MSc observed *in vivo*.

Introduction

CELLS COMMUNICATE AND exchange information by different ways, including the secretion of soluble factors, the cell-to-cell adhesion contact, and the intercellular exchange of organelles through nanotubular structures [1]. Recent studies have proposed that cell-derived small circular membrane vesicles, called exosomes (Exo) and microvesicles (MV), represent an additional mechanism of cell-to-cell communication by transfer of membrane components as well as the cytoplasmic content [2,3]. Shuttling of genetic material via cell membrane vesicles might have driven the unicellular organism evolution in the oceans. High frequency of horizontal gene transfer could explain the genomic flexibility of marine microbial populations that facilitated their adaptation to changing environmental conditions [4]. Cells physiologically release vesicles whose quantity generally increases upon cell activation after hypoxia, oxidative injury, exposure to complement proteins, and shear stress [2,5,6]. Two distinct populations of vesicles with peculiar membrane structure, mechanism of production, pathophysiological relevance, and different size have been described. Membrane fragments of 30–90 nm diameter derived from the endosomal membrane

compartment after fusion of secretory granules with the plasma membrane are defined as Exo. Once released, Exo bind the recipient cells through receptor–ligand interactions or fuse with the target cell membrane transferring membrane components, including cell receptors [2], and discharging the portion of cytosol segregated within their lumen into the cytoplasm of recipient cells [7]. The molecular cargo content of Exo derives from active packaging of certain nucleic acid species leading to the presence of mRNAs in Exo that are not found in donor cells [8]. Furthermore, relatively large MV (100 nm–1 μ m diameter) are formed from the surface membrane of activated cells in a calcium and calpain-dependent manner following a disordered function of phospholipid transporters that results in the budding of altered membrane that exposes phosphatidylserine in the outer leaflet. MV and Exo contain biomolecules, including mRNA and microRNA, packaged in a random process and their release is considered an expression of a pathological process in place. Molecular transfer from MV/Exo contributes to changes in the maturation and differentiation of target cells as MV/Exo released by endothelial progenitor cells trigger neo-angiogenesis in endothelial cells [9]. Consistently, embryonic stem (ES) cells released-MV/Exo are able to reprogram hematopoietic

¹Mario Negri Institute for Pharmacological Research, Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso, Bergamo, Italy.

²Laboratory of Cellular Therapy “G. Lanzani,” USC Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy.

³Unit of Nephrology and Dialysis, Azienda Ospedaliera, Ospedali Riuniti di Bergamo, Bergamo, Italy.

progenitor cells [10] and bone marrow–mesenchymal stem cells (BM-MSC)-derived MV/Exo have regenerative capacity [11]. BM-MSC contribute to organ repair by virtue of their unique tropism and proregenerative capacity [12–15]. In previous studies, we found that infusion of BM-MSC protected mice with cisplatin-induced acute kidney injury (AKI) from tubular damage and renal function deterioration by stimulating the proliferation of resident renal cells [12, 16]. The insulin-like growth factor-1 (IGF-1), highly expressed in BM-MSC as mRNA and protein, was a major mediator for such an effect as gene silencing of the IGF-1 in BM-MSC, significantly decreased *in vitro* proliferation and increased apoptosis of cocultured proximal tubular cells (proximal tubular epithelial cell [PTEC]) [17]. Consistently, IGF-1-silenced MSC displayed limited protection from functional and structural damage in mice with cisplatin-induced AKI [17]. The restricted homing of BM-MSC at the site of injury in the face of a robust functional recovery of the injured tissue [12,18] has raised the interest to investigate additional mechanisms that act in concert with the release of growth factors to explain the MSC's strong renoprotective effect. Here we sought to investigate whether a communication mechanism through Exo could operate between BM-MSC and damaged proximal tubular cells by shuttling mRNA.

Materials and Methods

Cell cultures and incubations

Human (h) MSC were obtained from BM aspirates collected from adult subjects (30–40 years old) within the Hematology Division, Azienda Ospedaliera, Ospedali Riuniti di Bergamo [19]. Human BM-MSC (hBM-MSC) were plated at 2×10^5 cells per cm^2 in the Dulbecco's modified Eagle's medium–low-glucose (DMEM–low glucose; Gibco) containing 0.1 mM gentamicin and 1,000 IU of heparin in the presence of 5% platelet lysate as previously described [19]. Nonadherent cells were removed after 3–4 days, and a fresh medium was added. At subconfluence, cells were recovered after trypsin-EDTA treatment, expanded, and subsequently characterized. By FACS analysis, human BM-MSC showed positivity for the CD29, CD90, CD73, and CD105 markers, and negativity for the hematopoietic markers CD45, CD34, CD14, and HLA-DR. Human BM-MSC had the capacity to differentiate toward adipocytes and osteoblasts [19,20]. All the experiments were performed with hBM-MSC derived from a pool of 3 donors between passages 5 and 8.

Mouse MSC derived from BM (mBM-MSC) of 2-month-old C57BL6/J mice [16] were obtained by their tendency to adhere tightly to plastic culture dishes [21]. Cells were plated at the density of $1 \times 10^6/\text{cm}^2$ in the DMEM plus 10% fetal calf serum (FCS; Invitrogen) and antibiotics [22]; after 6 h, non-adherent cells were removed. At 2 weeks, subconfluent mBM-MSC were immunodepleted of CD45⁺ cells, characterized for their ability to differentiate to adipocytes, osteoblasts, and chondroblasts [16] and used to isolate Exo.

Normal human dermal fibroblasts (NHDF) were obtained by Lonza. R- cells, a mouse fibroblast cell line knockout for the IGF-1R, were provided by Dr. Renato Baserga (Thomas Jefferson University, Philadelphia, PA) and were grown as previously described [23].

Human PTECs (HK2; American Type Culture Collection), were grown as previously described [24]. For evaluation of

horizontal transfer experiments, 5×10^5 cells were incubated with mBM-MSC-derived Exo for 1 and 3 h in the serum-deprived DMEM. After 3 washing steps with a $1 \times$ phosphate buffer solution (PBS), total RNA was extracted from HK2 and used for evaluation of mouse IGF-1R expression by real-time polymerase chain reaction (PCR).

The mouse PTEC line was provided by Dr. Eric G. Neilson (Vanderbilt University, Nashville, TN). PTECs were grown as described previously [25]. For *in vitro* studies, PTECs were seeded at 46×10^3 cells/ cm^2 and 24 h later incubated with the DMEM plus 2% FCS alone (test medium) or in the presence of 2.5 μM cis-platinum (II)-diamine dichloride (cisplatin; Sigma-Aldrich) for 6 h [17]. To study the effect of Exo on tubular cell proliferation in coculture, cisplatin-pretreated PTECs were incubated with a test medium or hBM-MSC-derived Exo (corresponding to a final concentration of 1 $\mu\text{g}/\text{mL}$ of Exo proteins) or IGF-1 (5 ng/mL) [17] or both for 4 days. PTECs in the test medium served as controls. After 4 days, PTEC proliferation was estimated by cell count using trypan blue dye exclusion (Sigma-Aldrich).

Isolation of Exo

Enriched preparations of Exo were purified as previously described [8,9,11]. Briefly, hBM-MSC were cultured for 48 h in a medium containing platelet lysate previously ultracentrifuged overnight at 100,000 g at 4°C to remove exogenous MV and Exo. Mouse BM-MSC or NHDF were cultured for 48 h in a medium containing FCS ultracentrifuged as above. Exo were then obtained from conditioned supernatants of human or mouse BM-MSC and NHDF cultured for 18 h in the DMEM–low-glucose medium deprived of platelet lysate or FCS, respectively. After centrifugation at 2000 g for 20 min and filtration through 0.2- μm filters to remove cell debris and particles larger than 200 nm, cell-free supernatants were ultracentrifuged at 100,000 g for 1 h at 4°C, washed in PBS, and submitted to a second ultracentrifugation at the same condition. The Exo pellet was suspended in 100 μL PBS and the protein content quantified by the Bradford method (BioRad). For *in vitro* experiments, the Exo pellet was suspended in the culture medium. In selected experiments, Exo were treated with 10 $\mu\text{g}/\text{mL}$ of RNase A (Ambion Inc.) for 1 h at 37°C, the reaction was stopped by the addition of a 10 U/mL RNase inhibitor (Ambion), and Exo were washed by ultracentrifugation. The effectiveness of RNase treatment was evaluated after RNA extraction using the Trizol reagent (Invitrogen) and submitted to reverse transcription (RT)-PCR analysis.

Electron microscopy analysis

The Exo pellet from hBM-MSC was fixed in 2% paraformaldehyde, and then loaded to copper grids (100 mesh) coated with Formvar. After washing, the grids were contrasted in 2% uranyl acetate, dried, and then examined by transmission electron microscopy (Morgagni 268D; Philips). The identity of the vesicles as Exo has been confirmed by the presence of the tetraspan surface proteins CD63 and CD9 by immunogold labeling of the grids over night at room temperature with primary antibodies (dilution 1:100 for CD63, BD Pharmingen; dilution 1:100 for CD9, Santa Cruz Biotechnology, Inc). In addition, the presence of the IGF-1R

protein has been evaluated by immunogold labeling of the grids over night at room temperature with a primary antibody (dilution 1:50, Abcam, ab5497). As a positive control, immunogold labeling for IGF-1R was concomitantly performed on thin sections of human renal tissue obtained from a patient who had undergone nephrectomy for kidney adenocarcinoma. The grids were then exposed for 1 h to species-specific anti-IgG antibodies conjugated to colloidal particles: 6 nm for CD9 and 12 nm for CD63 and IGF-1R detection. Human BM-MSC cultured on filters were fixed by immersion in 2.5% glutaraldehyde in a 0.1 M cacodylate buffer (pH 7.4) for 1 h at 4°C, and then washed in the cacodylate buffer. Strips of filter of 2 mm × 1 cm were cut with a razor blade and subsequently postfixed in 1% osmium tetroxide for 1 h, dehydrated through ascending grades of alcohol, and embedded in Epon resin. Semithin sections were stained with toluidine blue in borax and examined by light microscopy. Ultrathin sections (60 to 100 nm) were cut on an ultramicrotome (Leica Microsystems EM UC7), collected on copper grids, and stained with uranyl acetate and lead citrate, and then examined by transmission electron microscopy (Morgagni 268D; Philips).

Quantification of DNA and RNA in Exo

DNA and RNA from hBM-MSC-derived Exo were isolated using Trizol (Invitrogen) according to the manufacturer's protocol or using the RNeasy mini kit (Qiagen), suspended in 10 µL RNase-free water, and quantified by Nanodrop ND-1000.

Reverse transcription-polymerase chain reaction end point

RT-PCR analysis for IGF-1 and IGF-1R was performed on hBM-MSC or NHDF and their relative-derived Exo. GAPDH gene expression has been evaluated on hBM-MSC and their Exo, treated or not with RNase A. First-strand cDNA was produced from 0.5 µg total RNA using the SuperScript II First-Strand Synthesis Systems Kit (Invitrogen). No enzyme was added for reverse transcriptase-negative controls (RT-). The PCR protocol was 4 min at 94°C; 30 s at 94°C, 45 s at 56°C, 1 min at 72°C for 35 cycles; 72°C 5 min. The following primers were used: human IGF-1 (transcript of 349 bp), forward 5'-TGGATGCTCTTCAGTTCGTG-3' and reverse 5'-ACTCGTG CAGAGCAAAGGAT-3'; human IGF-1R (transcript of 351 bp), forward 5'-AACCCCAAGACTGAGGTGTG-3' and reverse 5'-ATCGATGCGGTACAATGTGA-3'; GAPDH (transcript of 450 bp), forward 5'-ACCACAGTCCATGCCATCAC-3' and reverse 5'-TCCACCACCCTGTTGCTGTA-3'. Samples were then separated on a 1.5% agarose gel. To evaluate the integrity of the IGF-1R mRNA into the Exo, first-strand cDNA was produced from 0.2 µg total RNA using the SuperScript II First-Strand Synthesis Systems Kit (Invitrogen). cDNA was submitted to PCR using the following primers: forward 5'-AAAAGGAATGAAGTCTGGCT-3' and reverse 5'-GGATC CAAGGATCAGCAGGT-3' (transcript of 4122 bp). The PCR protocol was 4 min at 94°C; 45 s at 94°C, 45 s at 58°C, 5 min at 72°C for 40 cycles; 72°C 10 min.

Quantitative real-time PCR

Total RNA was extracted from cells and Exo using the Trizol reagent and contaminating genomic DNA in murine

and human cells were removed by RNase-free DNase (Promega) for 1 h at 37°C. The first-strand cDNA (1 µg for R- and HK2 cells or 0.15 µg for hBM-MSC silenced for IGF-1R and their respective Exo) was produced using a mixture of oligo-dT (0.25 µg) and random eximers oligonucleotides (50 ng) and 200 U of SuperScript II RT (Invitrogen) for 1 h at 42°C. No enzyme was added for reverse transcriptase-negative controls (RT-).

Amplification was performed on the 7300 Real-Time PCR System with the SYBR Green PCR Master Mix (Applied Biosystems) according to the manufacturer's protocol. After an initial hold of 2 min at 50°C and 10 min at 95°C, the samples were cycled 40 times at 95°C for 15 s and 60°C for 60 s to reach the plateau. The comparative Ct method normalizes the number of target gene copies to the housekeeping gene as 18S (ΔCt). Gene expression was then evaluated by the quantification of cDNA corresponding with the target gene relative to a calibrator sample serving as a physiologic reference ($\Delta\Delta Ct$). On the basis of exponential amplification of the target gene as well as the calibrator, the amount of amplified molecules at the threshold cycle is given by: $2^{-\Delta\Delta Ct}$. The following primers were used: human IGF-1 receptor (300 nM): forward 5'-CCGGAATTGCATGGTAGCC-3' reverse 5'-GCGTCATACCAAATCTCCGA-3'; mouse IGF-1 receptor (300 nM): forward 5'-TAGGAACTGCATGGTAG CC-3' reverse 5'-GTGTCATACCGAAATCTCCAA-3'; 18S (50 nM) forward 5'-ACGGCTACCACATCCAAGGA-3', reverse 5'-CGGGAGTGGGGTAATTTGCG-3'; human BCL2-like1 (300 nM): forward 5'-TTCCTTCGGCGGGGCACT-3'; reverse 5'-AAGTATCCCAGCCGCCGTTCT-3'.

For real-time PCR array, total RNA was extracted from human and mouse BM-MSC and their respective Exo using the Qiagen RNeasy Mini kit, and cDNA (0.5–1 µg) was synthesized with the RT² First-Strand Kit following the manufacturer's procedure. The human Insulin Signaling Pathway RT² Profiler PCR Array (PAHS-030A; SABiosciences, Qiagen), the human PI3K/AKT Signaling Pathway RT² Profiler (PAHS-058A), the mouse Insulin Signaling Pathway RT² Profiler PCR Array (PAMM-030A), and the mouse PI3K/AKT Signaling Pathway RT² Profiler (PAMM-058A) were used.

Immunofluorescence

After 24 h exposition to hBM-MSC-derived exosomes (hExo), R- cells were fixed in 2% paraformaldehyde plus 4% sucrose in PBS, pH 7.4, for 10 min at 37°C, and then permeabilized with 0.3% Triton for 10 min at room temperature. After 3 washings with PBS, nonspecific binding sites were saturated in a blocking solution (5% FCS, 2% bovine serum albumin, and 0.2% bovine gelatin in PBS) for 45 min at room temperature. R- cells were then incubated overnight at 4°C with a rabbit polyclonal anti-IGF-1R β antibody detecting the cytoplasmic domain of the receptor (Santa Cruz Biotechnology, sc-713, dilution 1:100). A FITC-conjugated goat anti-rabbit IgG (Jackson ImmunoResearch Laboratories, dilution 1:50) was then added for 1 h at room temperature. DAPI staining was used to visualize nuclei. Representative images were acquired with an inverted confocal laser-scanning microscope. Human BM-MSC expressing IGF-1R were used as a positive control. A negative control was performed on R- not receiving the Exo and on R- omitting the primary antibody. The number of cells positive for IGF-1R was evaluated




FIG. 1. Electron microscopy analysis of exosomes. (A and B) Representative micrographs of transmission electron microscopy on human exosome preparations. Electron micrographs of CD63 (C) and CD9 (D) immunogold labeling of exosomes derived from human bone marrow–mesenchymal stem cells (hBM-MSC). (E and F) Representative micrographs of transmission electron microscopy on hBM-MSC monolayer releasing microvesicles and exosomes.

in at least 10 randomly selected high-power microscope fields ($\times 40$) and related to the total number of Dapi-positive cells in each field. Percentage is expressed as mean \pm SE of 3 independent experiments.

Silencing of IGF-1 receptor

Human BM-MSC were transfected with ON-TARGETplus SMARTpool siRNA (200pmoli) duplex specific for the target sequence NM_000875 (L-003012-00-00050, 5 nmol Dharmacon Inc.), or with control nontarget siRNA (Ambion, Silencer Select Negative Control #2 siRNA) using the Amaxa Human MSC Nucleofector Kit (VPE-1001 LONZA) according to the manufacturer's protocol. After transfection, cells were cultured for 24 h in the DMEM containing platelet lysate previously ultracentrifugated. Exo were then obtained from conditioned supernatants of hBM-MSC maintained for 18 h in the DMEM-low-glucose medium deprived of platelet lysate.

Statistical analysis

Results are expressed as mean \pm S.E. Analysis of variance (ANOVA) with Bonferroni or Tukey correction, or the Student's *t* test for unpaired data were used, as appropriate. Statistical significance is defined as $P < 0.05$.

Results

Characterization of human BM-MSC-derived Exo

In our experimental conditions, hBM-MSC released Exo, which were identified in the conditioned medium by electron microscopy as rounded structures of approximately 40–

100 nm (Fig. 1A, B). The expression of the CD63 and CD9 tetraspan surface proteins by immunogold labeling confirmed the presence of Exo in the preparations (Fig. 1C, D). Electron microscopy performed on the hBM-MSC monolayer cultured overnight in serum-free conditions showed also the presence of larger vesicles, possibly MV or multivesicular bodies, in the cell cytoplasm (Fig. 1E) that were released from the surface of hBM-MSC (Fig. 1F).

The concentration of Exo total proteins ranged from 12 to 25 ng/ μ L. Besides protein, Exo contain nucleic acids [8,9]. No DNA was found in Exo isolated from hBM-MSC either by nanodrop spectrophotometer quantification or 1% agarose gel electrophoresis (data not shown). By contrast, substantial amount of mRNA was detected whose concentration ranged from 30 to 150 ng/ μ L. These data are in line with a very recently published study [26]. To further confirm the presence of mRNA in Exo, purified preparations were treated with RNase A before RNA extraction. RT-PCR analysis for GAPDH did not show any band in the RNase A-treated Exo (Supplementary Fig. S1; Supplementary Data are available online at www.liebertpub.com/scd).

Analysis of the mRNA content in Exo

Our previous observation demonstrated that IGF-1 released by mBM-MSC recruited at the site of injury was one of the major mediators in inducing kidney recovery after acute injury [17]. Starting from this point, we performed PCR arrays to determine the expression profile of genes involved in the insulin signaling and in the PI3K-AKT signaling pathways in hBM-MSC and in hExo. A representative scatter plot showing the correlation in the gene expression levels ($2^{-\Delta\Delta C_t}$)

of the insulin-signaling pathway within donor cells and Exo is shown in Fig. 2A. Relative expression levels for each gene from hBM-MSC are plotted against the corresponding expression in Exo in triplicate experiments. The points that fall between the 2 external lines represent mRNAs with similar levels of expression in hBM-MSC and hExo, while those falling above or below the lines represent genes that are more expressed in hBM-MSC or in hExo, respectively. The majority of genes showed comparable expression levels between samples in both arrays. In the IGF-1 signaling pathway, hBM-MSC expressed both IGF-1 and IGF1-receptor (IGF-1R) mRNAs, while Exo contained the IGF-1R, but not the IGF-1 transcript. These results were further confirmed by RT-PCR analysis (Fig. 2B). To assess the integrity of IGF-1R

mRNA detected in hBM-MSC-derived Exo, RT-PCR analysis with primers that covered the entire length of the human IGF-1R mRNA was performed. As shown in Fig. 2D, a band of the predicted size was detected by gel electrophoresis in hExo.

To assess whether segregation of IGF-1/IGF-1R transcripts was confined to hExo, PCR arrays were also performed in Exo derived from mouse BM-MSC. Mouse Exo carried IGF-1R mRNA, but not the IGF-1 transcript, suggesting that segregation of mRNAs within the insulin-signaling pathway was shared between species. Transfer of selected transcripts was instead peculiar for BM-MSC since Exo derived from NHDF did not contain either IGF-1 or its receptor (Fig. 2C). The presence of IGF-1R into the hBM-MSC-derived Exo was not a random event since other receptors, such as the insulin receptor (INSR), or the peroxisome proliferator-activated receptor gamma (PPARG) were not detected in the Exo.

Exo-mediated horizontal transfer of mRNA as mechanism of intercellular communication

To evaluate whether IGF-1R mRNA could be shuttled from Exo to recipient cells, we elected to perform experiments in the R- mouse fibroblast cell line, obtained from mouse embryos homozygous for a targeted disruption of the *Igf1r* encoding the type 1 insulin-like growth factor receptor [23]. R- cells were incubated with hExo for 3h in a serum-free medium (Fig. 3A). To discard contaminant hExo not incorporated in the cells, 3 washing steps were performed at the end of incubation and total RNA was extracted from R- cells or Exo and analyzed for IGF-1R gene expression by RT-PCR analysis using primers specific for the human transcript. As shown in Fig. 3B, the IGF-1R transcript was detected in hExo and R- cells incubated with human Exo, but not in R- control cells.

To demonstrate that the transferred mRNA was intact and functional, we performed immunofluorescence experiments to detect the translated protein in the target cells. Due to the high homology between the human and mouse IGF-1R proteins, the commercially available antibodies for IGF-1R do not discriminate the 2 sequences, a problem that was overcome by using R- as recipient cells. R- cells were exposed to human Exo and immunofluorescence was performed 24 h later. As depicted in Fig. 3C, the staining of IGF-1R was clearly present in the R- cells exposed to human Exo (panel b), but not in untreated cells (panel c). Human BM-MSC, taken as a positive control, show intense staining of IGF-1R (panel a). No staining was observed in the negative control confirming the specificity of the signal. The percentage of R-cells that expressed the Exo-derived hIGF-1R protein was on average $24.2\% \pm 7.7\%$. To assess whether the IGF-1R protein could be present in Exo, contributing to a direct transfer of the protein, Exo were labeled for IGF-1R by immunogold, but no labeling was observed (data not shown).

Horizontal transfer of IGF-1R mRNA also occurred when mouse Exo were added to HK2 cells for 1 and 3 h. Using specific primers for mouse sequence, IGF-1R expression increased in HK2 exposed to mouse Exo. The increase was time-dependent suggesting at best that IGF-1R expression was due to the mRNA transfer instead of residual Exo RNA. As expected, no mouse transcript was detected in control HK2 (Fig. 3D).




FIG. 2. Gene expression profile in hBM-MSC and normal human dermal fibroblasts (NHDF) and their relative exosomes. (A) Representative scatter plot generated by the polymerase chain reaction (PCR) array to determine the expression profile of genes involved in the insulin-signaling pathway in hBM-MSC and their corresponding exosomes. (B) Reverse transcription (RT)-PCR analysis for insulin-like growth factor-1 (IGF-1) and IGF-1 receptor (IGF-1R) on hBM-MSC and their respective exosomes and (C) on NHDF and their respective exosomes. (D) RT-PCR analysis for human IGF-1R full length (transcript of 4122 bp) in human exosomes (hExo). RT- represents negative controls obtained by omitting reverse transcriptase enzyme.




FIG. 3. Horizontal transfer of mRNA through human exosomes. **(A)** Experimental design of horizontal transfer. **(B)** RT-PCR for human IGF-1R on mRNA extracted from mouse R-cells exposed or not for 3 h to hBM-MSC-derived exosomes using primers specific for the human IGF-1R sequence. As a positive control, RT-PCR was performed on mRNA extracted from hExo. A transcript of 350 bp was clearly detected both in R-cells exposed to hExo and in exosome preparation, but not in untreated mouse R-cells. **(C)** Immunofluorescence staining for human IGF-1R in mouse R-cells exposed or not to hExo. The specificity of the staining was confirmed on hBM-MSC **(a)**. Exosome-derived expression of hIGF-1R was detected in R-cells exposed to hExo **(b)**. Negative control was performed on R-cells not receiving the hExo **(c)**. Original magnification, $\times 400$. **(D)** Representative 4% agarose gel electrophoresis of the real-time PCR amplification products (expected size of 60 bp) and their relative quantification (*bottom*) for mouse IGF-1R on mRNA from HK2 untreated or exposed for 1 or 3 h to mouse BM-MSC-derived exosomes. RT- represents negative controls. Results are expressed as mean \pm S.E ($n=3$). Analysis of variance with Bonferroni correction was performed; * $P < 0.05$ and ** $P < 0.01$ versus HK2.

Human BM-MSC-derived Exo induce regeneration of damaged proximal tubular epithelial cells

The ability of hBM-MSC-derived Exo to stimulate proliferation was investigated using an in vitro model of cisplatin-induced toxicity in mouse PTEC [17]. Mouse PTEC were exposed to cisplatin for 6 h. After drug withdrawal, PTEC were incubated with Exo from the hBM-MSC-conditioned medium, or with 5 ng/mL of IGF-1, or both. Proliferation of damaged PTEC, evaluated 4 days after the beginning of the incubation, was significantly increased following the addition of hExo or IGF-1 alone. Coincubation of damaged PTEC with hExo and soluble IGF-1 further enhanced cell proliferation in respect to single treatments (Fig. 4).

Gene silencing of IGF-1R in human BM-MSC reduces the proliferative effect of Exo

To study the possible role of IGF-1R mRNA delivered to PTEC by Exo in potentiating the proliferative effect of IGF-1 on PTEC, we silenced the expression of IGF-1R in hBM-MSC before Exo purification. Preliminary experiments were performed to optimize the dose of siRNA to silence IGF-1R expression in hBM-MSC (Fig. 5A). Real-time RT-PCR experiments showed 80% inhibition of IGF-1R expression in hBM-MSC and no transcript was detected in Exo preparations (Fig. 5B). When damaged PTEC cells were exposed to Exo derived from IGF-1R-silenced hBM-MSC (hExo-siIGF-1R), IGF-1-induced proliferation was significantly reduced as compared to that of cells incubated with Exo from scramble




FIG. 4. Proliferation of damaged mouse proximal tubular epithelial cells (PTEC). PTEC were exposed to cisplatin 2.5 μ M for 6h, and then incubated with test medium or hBM-MSC-derived exosomes or IGF-1 (5 ng/mL) or both for 4 days. PTEC proliferation was estimated by cell count using trypan blue dye exclusion and PTEC+cispl was taken as 100%. Results are expressed as mean \pm S.E ($n=3$). Analysis of variance with Tukey correction was performed; * $P < 0.01$ versus PTEC + cispl; ^o $P < 0.05$ versus PTEC + cispl + hExo and PTEC + cispl + IGF-1.

siRNA-treated hBM-MSC (hExo-siScramble) (Fig. 6). To exclude the possibility that gene silencing could affect the Exo cargo content, we compared the expression of BCL2-like1 as the gene involved in the regenerative activity of BM-MSC, in IGF-1R-silenced or not Exo preparations. No significant difference in BCL2-like1 expression was observed in Exo preparations silenced or not for IGF-1R (data not shown).

Discussion

The present study demonstrates that hBM-MSC release into the culture medium heterogeneous populations of MV and Exo that do not contain DNA, but are engulfed with mRNA. Our previous data showed that BM-MSC release anti-inflammatory and pro-survival soluble factors, including TGF- β , IL-10, and IGF-1, the latter representing the best candidate for proximal tubular cell regeneration after AKI based on its proliferative and antiapoptotic properties [17]. Starting from this observation, we hypothesized that the effect of BM-MSC-released IGF-1 protein on proximal tubular cells could be amplified by increased expression of IGF-1 on tubular cells via Exo-mediated mRNA transfer. This, however, was not the case since analysis of the cargo content of hBM-MSC-derived Exo by PCR array did not show the presence of the IGF-1 transcript. We therefore reasoned that the paracrine effect of BM-MSC-derived IGF-1 on proximal tubular cells could be helped by the transfer of IGF-1R mRNA to the target cells. To lend further support to this hypothesis, PCR array data showed the presence of the IGF-1R mRNA in Exo from hBM-MSC that also was found to be intact by RT-PCR analysis.

We next evaluated whether the IGF-1R mRNA in Exo was horizontally transferred in recipient cells taking advantage from the availability of the IGF-1R null cells (R-). The R-fibroblast cell line, obtained from a mouse embryo lacking




FIG. 5. Gene silencing of IGF-1R in hBM-MSC. **(A)** Different amounts of small interfering RNA (siRNA) specific for human IGF-1R were tested to reach the highest efficiency of silencing. Results are expressed as mean \pm S.E ($n=3$). Analysis of variance with Bonferroni correction was performed; * $P < 0.01$ versus hBM-MSC. **(B)** Evaluation of IGF-1R mRNA in hBM-MSC and their derived exosomes after gene silencing (hExo-siIGF-1R). Analysis of variance with Bonferroni correction was performed; * $P < 0.001$ versus hBM-MSC.

IGF-1R, acquired the capability to express the IGF-1R protein after incubation with Exo derived from hBM-MSC. These data would indicate that the shuttling of IGF-1R mRNA from Exo to R- cells occurred and was accompanied by a cell phenotype change due to the translation of the transcript into the corresponding protein.

Selective differences in the expression of IGF-1/IGF-1R mRNAs in Exo derived from BM-MSC and parental cells as well as the horizontal transfer of mRNAs between Exo and proximal tubular cells is not restricted to hBM-MSC, but is a shared phenomenon with mouse BM-MSC. These data point to a novel mechanism that may operate in BM-MSC of different species accounting for their regenerative effect. Selective mRNA transfer into Exo supported the notion that the mRNA contained in the Exo is not an exact copy of the mRNAs of the donor cells as previously observed in mast cells [8]. This observation was further supported by the finding that mRNAs for other receptors in the insulin-signaling pathway like the INSR or the PPAR γ were not found in hBM-MSC-derived Exo. Specific targeting of the IGF-1R mRNA sequence in the Exo is specific for BM-MSC since Exo derived from NHDF did not contain either IGF-1 or its




FIG. 6. Effect of IGF-1R silencing on proliferation of damaged mouse PTEC. PTEC were exposed to IGF-1 and exosomes derived from hBM-MSC treated with scramble siRNA (hExo-siScramble) or siRNA specific for IGF-1R (hExo-siIGF-1R). PTEC were exposed to medium or cisplatin 2.5 μ M for 6h, and then incubated with test medium or with IGF-1 and hExo preparations. PTEC proliferation was estimated after 4 days by cell count using trypan blue dye exclusion and PTEC+cispl was taken as 100%. Results are expressed as mean \pm S.E ($n=4$). Analysis of variance with Bonferroni correction was performed; * $P < 0.05$ versus PTEC+cispl, ° $P < 0.05$ versus PTEC+cispl+IGF-1+hExo-siScramble.

receptor mRNAs. It is still unclear why a set of specific mRNA transcripts is differentially shuttled to Exo in various cell types. Understanding such a mechanism would help to understand the function of RNA delivery to secreted vesicles.

The use of an in vitro model of cisplatin-induced toxicity in proximal tubular cells allowed to demonstrate that the transfer of IGF-1R mRNA through Exo resulted into a functional effect as documented by increased proliferation of the damaged proximal tubular cells exposed to Exo. Silencing the expression of IGF-1R in hBM-MSC before Exo production strongly limited proliferation of tubular cells induced by Exo further reinforcing the concept of IGF-1R being involved in the functional effect. We cannot exclude that gene silencing could have altered the cargo content of Exo, modulating the expression of genes that exacerbate the inhibitory effect on tubular cell proliferation, although no significant changes in the expression of the antiapoptotic gene BCL2-like1 were observed in IGF-1R-silenced Exo in respect to unmodified Exo. Addition of exogenous IGF-1 induced an increase in the growth of cisplatin-treated tubular cells that was further enhanced by cell exposure to the IGF-1 protein and Exo in respect to treatments given alone. It is conceivable that sensitivity of proximal tubular cells to IGF-1 could be enhanced by the transfer of IGF-1R mRNA via Exo. This phenomenon would explain the ability of a low number of MSC engrafting the kidney to promote a prompt recovery from AKI [17].

The present data provide for the first time the evidence of a specific mechanism through which BM-MSC contribute to repair the injured tissue by virtue of a combined trophic effect induced by a soluble factor and the expression of the corre-

sponding receptor in the target cells after the transfer of genetic material accomplished by Exo. Exo have the capacity to communicate messages to repair damaged cells as demonstrated for mast cells that exposed to oxidative stress-released Exo containing protective signals making the recipient cell more tolerant to oxidative processes and to cell death [27]. Besides functional mRNA, Exo contain microRNAs (miRNAs) [28,29], small noncoding RNAs that regulate gene expression at the post-transcriptional level [30]. MicroRNAs control cell fate and behavior by repressing the translation of selected mRNAs in stem cells as well as in differentiating daughter cells [31]. The presence of miRNAs into Exo from mast cells [8], ES cells [32], and BM-MSC [28,29] has been taken to suggest that they act as regulators of cell-cell communication by modulating the fate and behavior of target cells via epigenetic changes of their transcriptome. Whether the regenerative potential of BM-MSC can be attributed to a fine regulation of protein translation by miRNAs will be a matter of future investigation. In conclusion, BM-MSC recruited to the site of injury may reprogram the damaged cells stimulating their proliferation and favoring tissue regeneration through the contribution of growth factors and the transfer of genetic material by Exo both locally released by BM-MSC.

Acknowledgments

We thank Dr. Elena Gagliardini and Daniela Cavallotti for the excellent technical assistance. We are greatly indebted to Dr. Renato Baserga (Thomas Jefferson University, Philadelphia, PA) for providing the R- mouse cell line. C.R. is a recipient of a fellowship from Fondazione Aiuti per la Ricerca sulle Malattie Rare (ARMR), Bergamo, Italy. This work was partially supported by a grant from Genzyme Renal Innovations Program (GRIP) and from Ministero della Salute, Bando Cellule Staminali 2008, Codice Progetto B11J11001110002. Part of the research leading to these results has received funding from the European Community under the European Community's Seventh Framework Programme (FP7/2007-2013), grant number 223007, STAR-T REK project.

Author Disclosure Statement

No competing financial interests exist.

References

1. Rustom A, R Saffrich, I Markovic, P Walther and HH Gerdes. (2004). Nanotubular highways for intercellular organelle transport. *Science* 303:1007-1010.
2. Ratajczak J, M Wysoczynski, F Hayek, A Janowska-Wieczorek and MZ Ratajczak. (2006). Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. *Leukemia* 20:1487-1495.
3. Camussi G, MC Deregibus, S Bruno, V Cantaluppi and L Biancone. (2010). Exosomes/microvesicles as a mechanism of cell-to-cell communication. *Kidney Int* 78:838-848.
4. McDaniel LD, E Young, J Delaney, F Ruhnu, KB Ritchie and JH Paul. (2010). High frequency of horizontal gene transfer in the oceans. *Science* 330:50.
5. Denzer K, MJ Kleijmeer, HF Heijnen, W Stoorvogel and HJ Geuze. (2000). Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. *J Cell Sci* 113 Pt 19:3365-3374.

6. Fevrier B and G Raposo. (2004). Exosomes: endosomal-derived vesicles shipping extracellular messages. *Curr Opin Cell Biol* 16:415–421.
7. Cocucci E, G Racchetti and J Meldolesi. (2009). Shedding microvesicles: artefacts no more. *Trends Cell Biol* 19:43–51.
8. Valadi H, K Ekstrom, A Bossios, M Sjostrand, JJ Lee and JO Lotvall. (2007). Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat Cell Biol* 9:654–659.
9. Deregibus MC, V Cantaluppi, R Calogero, M Lo Iacono, C Tetta, L Biancone, S Bruno, B Bussolati and G Camussi. (2007). Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA. *Blood* 110:2440–2448.
10. Ratajczak J, K Miekus, M Kucia, J Zhang, R Reza, P Dvorak and MZ Ratajczak. (2006). Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. *Leukemia* 20:847–856.
11. Bruno S, C Grange, MC Deregibus, RA Calogero, S Saviozzi, F Collino, L Morando, A Busca, M Falda, et al. (2009). Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. *J Am Soc Nephrol* 20:1053–1067.
12. Morigi M, M Introna, B Imberti, D Corna, M Abbate, C Rota, D Rottoli, A Benigni, N Perico, et al. (2008). Human bone marrow mesenchymal stem cells accelerate recovery of acute renal injury and prolong survival in mice. *Stem Cells* 26:2075–2082.
13. Chhabra P and KL Brayman. (2009). The use of stem cells in kidney disease. *Curr Opin Organ Transplant* 14:72–78.
14. Aejaz HM, AK Aleem, N Parveen, MN Khaja, ML Narusu and CM Habibullah. (2007). Stem cell therapy—present status. *Transplant Proc* 39:694–699.
15. Salem HK and C Thiemermann. (2010). Mesenchymal stromal cells: current understanding and clinical status. *Stem Cells* 28:585–596.
16. Morigi M, B Imberti, C Zoja, D Corna, S Tomasoni, M Abbate, D Rottoli, S Angioletti, A Benigni, et al. (2004). Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. *J Am Soc Nephrol* 15:1794–1804.
17. Imberti B, M Morigi, S Tomasoni, C Rota, D Corna, L Longaretti, D Rottoli, F Valsecchi, A Benigni, et al. (2007). Insulin-like growth factor-1 sustains stem cell mediated renal repair. *J Am Soc Nephrol* 18:2921–2928.
18. Togel F, Z Hu, K Weiss, J Isaac, C Lange and C Westfelder. (2005). Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. *Am J Physiol Renal Physiol* 289:F31–F42.
19. Capelli C, M Domenghini, G Borleri, P Bellavita, R Poma, A Carobbio, C Mico, A Rambaldi, J Golay and M Introna. (2007). Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts. *Bone Marrow Transplant* 40:785–791.
20. Capelli C, E Gotti, M Morigi, C Rota, L Weng, F Dazzi, O Spinelli, G Cazzaniga, R Trezzi, et al. (2011). Minimally manipulated whole human umbilical cord is a rich source of clinical-grade human mesenchymal stromal cells expanded in human platelet lysate. *Cytotherapy* 13:786–801.
21. Pereira RF, KW Halford, MD O'Hara, DB Leeper, BP Sokolov, MD Pollard, O Bagasra and DJ Prockop. (1995). Cultured adherent cells from marrow can serve as long-lasting precursor cells for bone, cartilage, and lung in irradiated mice. *Proc Natl Acad Sci U S A* 92:4857–4861.
22. Phinney DG, G Kopen, RL Isaacson and DJ Prockop. (1999). Plastic adherent stromal cells from the bone marrow of commonly used strains of inbred mice: variations in yield, growth, and differentiation. *J Cell Biochem* 72:570–585.
23. Sell C, G Dumenil, C Deveaud, M Miura, D Coppola, T DeAngelis, R Rubin, A Efstratiadis and R Baserga. (1994). Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. *Mol Cell Biol* 14:3604–3612.
24. Morigi M, D Macconi, C Zoja, R Donadelli, S Buelli, C Zanchi, M Ghilardi and G Remuzzi. (2002). Protein overload-induced NF-kappaB activation in proximal tubular cells requires H(2)O(2) through a PKC-dependent pathway. *J Am Soc Nephrol* 13:1179–1189.
25. Haverly TP, CJ Kelly, WH Hines, PS Amenta, M Watanabe, RA Harper, NA Kefalides and EG Neilson. (1988). Characterization of a renal tubular epithelial cell line which secretes the autologous target antigen of autoimmune experimental interstitial nephritis. *J Cell Biol* 107:1359–1368.
26. Eldh M, J Lotvall, C Malmhall and K Ekstrom. (2012). Importance of RNA isolation methods for analysis of exosomal RNA: evaluation of different methods. *Mol Immunol* 50:278–286.
27. Eldh M, K Ekstrom, H Valadi, M Sjostrand, B Olsson, M Jernas and J Lotvall. (2010). Exosomes communicate protective messages during oxidative stress; possible role of exosomal shuttle RNA. *PLoS One* 5:e15353.
28. Chen TS, RC Lai, MM Lee, AB Choo, CN Lee and SK Lim. (2010). Mesenchymal stem cell secretes microparticles enriched in pre-microRNAs. *Nucleic Acids Res* 38:215–224.
29. Collino F, MC Deregibus, S Bruno, L Sterpone, G Aghemo, L Viltono, C Tetta and G Camussi. (2010). Microvesicles derived from adult human bone marrow and tissue specific mesenchymal stem cells shuttle selected pattern of miRNAs. *PLoS One* 5:e11803.
30. Filipowicz W, SN Bhattacharyya and N Sonenberg. (2008). Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? *Nat Rev Genet* 9:102–114.
31. Gangaraju VK and H Lin. (2009). MicroRNAs: key regulators of stem cells. *Nat Rev Mol Cell Biol* 10:116–125.
32. Yuan A, EL Farber, AL Rapoport, D Tejada, R Deniskin, NB Akhmedov and DB Farber. (2009). Transfer of microRNAs by embryonic stem cell microvesicles. *PLoS One* 4:e4722.

Address correspondence to:

Dr. Susanna Tomasoni

Mario Negri Institute for Pharmacological Research

Centro Anna Maria Astori

Science and Technology Park Kilometro Rosso

Via Stezzano, 87

Bergamo 24126

Italy

E-mail: susanna.tomasoni@marionegri.it

Received for publication May 16, 2012

Accepted after revision October 19, 2012

Prepublished on Liebert Instant Online October 19, 2012

This article has been cited by:

1. Johannes Leibacher, Reinhard Henschler. 2016. Biodistribution, migration and homing of systemically applied mesenchymal stem/stromal cells. *Stem Cell Research & Therapy* 7. . [[CrossRef](#)]
2. Soraia C. Abreu, Daniel J. Weiss, Patricia R. M. Rocco. 2016. Extracellular vesicles derived from mesenchymal stromal cells: a therapeutic option in respiratory diseases?. *Stem Cell Research & Therapy* 7:1. . [[CrossRef](#)]
3. Antoine Monsel, Ying-gang Zhu, Varun Gudapati, Hyungsun Lim, Jae W. Lee. 2016. Mesenchymal stem cell derived secretome and extracellular vesicles for acute lung injury and other inflammatory lung diseases. *Expert Opinion on Biological Therapy* 16:7, 859-871. [[CrossRef](#)]
4. Stefania Bruno, Stefano Porta, Benedetta Bussolati. 2016. Extracellular vesicles in renal tissue damage and regeneration. *European Journal of Pharmacology* . [[CrossRef](#)]
5. S. Manoj Kumar Kingsley, B. Vishnu Bhat. 2016. Could stem cells be the future therapy for sepsis?. *Blood Reviews* . [[CrossRef](#)]
6. Terrence M. Rager, Jacob K. Olson, Yu Zhou, Yijie Wang, Gail E. Besner. 2016. Exosomes secreted from bone marrow-derived mesenchymal stem cells protect the intestines from experimental necrotizing enterocolitis. *Journal of Pediatric Surgery* 51:6, 942-947. [[CrossRef](#)]
7. Sylwia Koniusz, Anna Andrzejewska, Maurizio Muraca, Amit K. Srivastava, Mirosław Janowski, Barbara Lukomska. 2016. Extracellular Vesicles in Physiology, Pathology, and Therapy of the Immune and Central Nervous System, with Focus on Extracellular Vesicles Derived from Mesenchymal Stem Cells as Therapeutic Tools. *Frontiers in Cellular Neuroscience* 10. . [[CrossRef](#)]
8. B. D. Humphreys, V. Cantaluppi, D. Portilla, K. Singbartl, L. Yang, M. H. Rosner, J. A. Kellum, C. Ronco. 2016. Targeting Endogenous Repair Pathways after AKI. *Journal of the American Society of Nephrology* 27, 990-998. [[CrossRef](#)]
9. Kyung Hyun Moon, In Kap Ko, James J. Yoo, Anthony Atala. 2016. Kidney diseases and tissue engineering. *Methods* 99, 112-119. [[CrossRef](#)]
10. A. Gooch, C. Westenfelder. 2016. Modified Hydrogels to Enhance Cellular Therapy for AKI: A Translational Challenge. *Journal of the American Society of Nephrology* . [[CrossRef](#)]
11. Xie Lili, Mao Mao, Zhou Liang, Jiang Bing. 2016. Spheroid Mesenchymal Stem Cells and Mesenchymal Stem Cell-Derived Microvesicles: Two Potential Therapeutic Strategies. *Stem Cells and Development* 25:3, 203-213. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
12. Uta Erdbrügger, Joanne Lannigan. 2016. Analytical challenges of extracellular vesicle detection: A comparison of different techniques. *Cytometry Part A* 89:10.1002/cyto.a.v89.2, 123-134. [[CrossRef](#)]
13. Deena A. Rennerfeldt, Krystyn J. Van Vliet. 2016. When colonies are not clones: Evidence and implications of intracolony heterogeneity in mesenchymal stem cells. *STEM CELLS* n/a-n/a. [[CrossRef](#)]
14. Muhammad Nawaz, Farah Fatima, Krishna C. Vallabhaneni, Patrice Penfornis, Hadi Valadi, Karin Ekström, Sharad Kholia, Jason D. Whitt, Joseph D. Fernandes, Radhika Pochampally, Jeremy A. Squire, Giovanni Camussi. 2016. Extracellular Vesicles: Evolving Factors in Stem Cell Biology. *Stem Cells International* 2016, 1-17. [[CrossRef](#)]
15. Alejandro Luarte, Luis Federico Bátiz, Ursula Wyneken, Carlos Lafourcade. 2016. Potential Therapies by Stem Cell-Derived Exosomes in CNS Diseases: Focusing on the Neurogenic Niche. *Stem Cells International* 2016, 1-16. [[CrossRef](#)]
16. Marina Morigi, Cinzia Rota, Giuseppe Remuzzi Mesenchymal Stem Cells in Kidney Repair 89-107. [[CrossRef](#)]
17. Massimiliano Gnechi, Patrizia Danieli, Giuseppe Malpasso, Maria Chiara Ciuffreda Paracrine Mechanisms of Mesenchymal Stem Cells in Tissue Repair 123-146. [[CrossRef](#)]
18. Peter J. Quesenberry, Jason Aliotta, Maria Chiara Deregibus, Giovanni Camussi. 2015. Role of extracellular RNA-carrying vesicles in cell differentiation and reprogramming. *Stem Cell Research & Therapy* 6. . [[CrossRef](#)]
19. Stefania Bruno, Maria Chiara Deregibus, Giovanni Camussi. 2015. The secretome of mesenchymal stromal cells: Role of extracellular vesicles in immunomodulation. *Immunology Letters* 168, 154-158. [[CrossRef](#)]
20. Almudena Fuster-Matanzo, Florian Gessler, Tommaso Leonardi, Nunzio Iraci, Stefano Pluchino. 2015. Acellular approaches for regenerative medicine: on the verge of clinical trials with extracellular membrane vesicles?. *Stem Cell Research & Therapy* 6. . [[CrossRef](#)]
21. Zhuo Wang, Zhong Deng, Nadia Dahmane, Kevin Tsai, Pu Wang, Dewight R. Williams, Andrew V. Kossenkov, Louise C. Showe, Rugang Zhang, Qihong Huang, José R. Conejo-García, Paul M. Lieberman. 2015. Telomeric repeat-containing RNA (TERRA) constitutes a nucleoprotein component of extracellular inflammatory exosomes. *Proceedings of the National Academy of Sciences* 112:46, E6293-E6300. [[CrossRef](#)]

22. Adolf Geiger, Audrey Walker, Erwin Nissen. 2015. Human fibrocyte-derived exosomes accelerate wound healing in genetically diabetic mice. *Biochemical and Biophysical Research Communications* **467**, 303-309. [[CrossRef](#)]
23. Mirja Krause, Anatoliy Samoylenko, Seppo J. Vainio. 2015. Exosomes as renal inductive signals in health and disease, and their application as diagnostic markers and therapeutic agents. *Frontiers in Cell and Developmental Biology* **3**. [[CrossRef](#)]
24. Elena Lazzeri, Paola Romagnani, Laura Lasagni. 2015. Stem cell therapy for kidney disease. *Expert Opinion on Biological Therapy* **15**, 1455-1468. [[CrossRef](#)]
25. Kelvin S. Ng, Thomas M. Kunczewicz, Jeffrey M. Karp. 2015. Beyond Hit-and-Run: Stem Cells Leave a Lasting Memory. *Cell Metabolism* **22**, 541-543. [[CrossRef](#)]
26. Shabbir Arsalan, Cox Audrey, Rodriguez-Menocal Luis, Salgado Marcela, Badiavas Evangelos Van. 2015. Mesenchymal Stem Cell Exosomes Induce Proliferation and Migration of Normal and Chronic Wound Fibroblasts, and Enhance Angiogenesis In Vitro. *Stem Cells and Development* **24**:14, 1635-1647. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
27. An Zhao, Michel Péoc'h, Michèle Cottier, Christian Genin, Nicolas Mottet, Guorong Li. 2015. Cell-free RNA content in urine as a possible molecular diagnostic tool for clear cell renal cell carcinoma. *International Journal of Cancer* **136**:10.1002/ijc.v136.11, 2610-2615. [[CrossRef](#)]
28. James C. Lee, Jing-Ting Zhao, Justin Gundara, Jonathan Serpell, Leon A. Bach, Stan Sidhu. 2015. Papillary thyroid cancer-derived exosomes contain miRNA-146b and miRNA-222. *Journal of Surgical Research* **196**, 39-48. [[CrossRef](#)]
29. Sweta Rani, Aideen E Ryan, Matthew D Griffin, Thomas Ritter. 2015. Mesenchymal Stem Cell-derived Extracellular Vesicles: Toward Cell-free Therapeutic Applications. *Molecular Therapy* **23**, 812-823. [[CrossRef](#)]
30. Adriana Octaviana Dulamea. 2015. The potential use of mesenchymal stem cells in stroke therapy—From bench to bedside. *Journal of the Neurological Sciences* **352**, 1-11. [[CrossRef](#)]
31. Elizabeth B. Oliveira-Sales, Vanessa A. Varela, Cassia T. Bergamaschi, Ruy R. Campos, Mirian A. Boim. 2015. Effects of mesenchymal stem cells in renovascular hypertension. *Experimental Physiology* **100**, 491-495. [[CrossRef](#)]
32. Leon A. Bach, Lorna J. Hale. 2015. Insulin-like Growth Factors and Kidney Disease. *American Journal of Kidney Diseases* **65**, 327-336. [[CrossRef](#)]
33. A. Ranghino, V. Dimuccio, E. Papadimitriou, B. Bussolati. 2015. Extracellular vesicles in the urine: markers and mediators of tissue damage and regeneration. *Clinical Kidney Journal* **8**, 23-30. [[CrossRef](#)]
34. Jie Chen, Chonghui Li, Liangan Chen. 2015. The Role of Microvesicles Derived from Mesenchymal Stem Cells in Lung Diseases. *BioMed Research International* **2015**, 1-6. [[CrossRef](#)]
35. Bin Yu, Muhammad Ashraf, Meifeng Xu Therapeutic Potential of Stem Cell-Derived Extracellular Vesicles in Cardioprotection and Myocardium Repair 119-138. [[CrossRef](#)]
36. Clara Gallina, Valentina Turinetto, Claudia Giachino. 2015. A New Paradigm in Cardiac Regeneration: The Mesenchymal Stem Cell Secretome. *Stem Cells International* **2015**, 1-10. [[CrossRef](#)]
37. RosannaC Ching, PaulJ Kingham. 2015. The role of exosomes in peripheral nerve regeneration. *Neural Regeneration Research* **10**, 743. [[CrossRef](#)]
38. Hyun Chul Chung, In Kap Ko, Anthony Atala, James J. Yoo. 2015. Cell-based therapy for kidney disease. *Korean Journal of Urology* **56**, 412. [[CrossRef](#)]
39. Olivier G. De Jong, Bas W. M. Van Balkom, Raymond M. Schiffelers, Carlijn V. C. Bouten, Marianne C. Verhaar. 2014. Extracellular Vesicles: Potential Roles in Regenerative Medicine. *Frontiers in Immunology* **5**. [[CrossRef](#)]
40. Marialaura Madrigal, Kosagisharaf S Rao, Neil H Riordan. 2014. A review of therapeutic effects of mesenchymal stem cell secretions and induction of secretory modification by different culture methods. *Journal of Translational Medicine* **12**. [[CrossRef](#)]
41. Serhiy Forostyak, Ales Homola, Karolina Turnovcova, Pavel Svitil, Pavla Jendelova, Eva Sykova. 2014. Intrathecal Delivery of Mesenchymal Stromal Cells Protects the Structure of Altered Perineuronal Nets in SOD1 Rats and Amends the Course of ALS. *STEM CELLS* **32**:10.1002/stem.v32.12, 3163-3172. [[CrossRef](#)]
42. Hongqi Xin, Yi Li, Michael Chopp. 2014. Exosomes/miRNAs as mediating cell-based therapy of stroke. *Frontiers in Cellular Neuroscience* **8**. [[CrossRef](#)]
43. Antoine Monsel, Ying-gang Zhu, Stephane Gennai, Qi Hao, Jia Liu, Jae W. Lee. 2014. Cell-based Therapy for Acute Organ Injury. *Anesthesiology* **121**, 1099-1121. [[CrossRef](#)]
44. Pengfei Liu, Yetong Feng, Yi Wang, Yulai Zhou. 2014. Therapeutic action of bone marrow-derived stem cells against acute kidney injury. *Life Sciences* **115**, 1-7. [[CrossRef](#)]

45. Federica Collino, Stefania Bruno, Rafael Soares Lindoso, Giovanni Camussi. 2014. miRNA Expression in Mesenchymal Stem Cells. *Current Pathobiology Reports* **2**, 101-107. [[CrossRef](#)]
46. Stefania Bruno, Federica Collino, Alessandra Iavello, Giovanni Camussi. 2014. Effects of Mesenchymal Stromal Cell-Derived Extracellular Vesicles on Tumor Growth. *Frontiers in Immunology* **5**. . [[CrossRef](#)]
47. Xi Tan, Yong-Zhen Gong, Ping Wu, Duan-Fang Liao, Xi-Long Zheng. 2014. Mesenchymal Stem Cell-Derived Microparticles: A Promising Therapeutic Strategy. *International Journal of Molecular Sciences* **15**, 14348-14363. [[CrossRef](#)]
48. Daniëlle G. Leuning, Marlies E.J. Reinders, Johannes W. de Fijter, Ton J. Rabelink. 2014. Clinical Translation of Multipotent Mesenchymal Stromal Cells in Transplantation. *Seminars in Nephrology* **34**, 351-364. [[CrossRef](#)]
49. Milene R. da Costa, Luciana Pizzatti, Rafael S. Lindoso, Julliana Ferreira Sant'Anna, Barbara DuRocher, Eliana Abdelhay, Adalberto Vieyra. 2014. Mechanisms of kidney repair by human mesenchymal stromal cells after ischemia: A comprehensive view using label-free MS E. *PROTEOMICS* **14**:10.1002/pmic.v14.12, 1480-1493. [[CrossRef](#)]
50. Luca Braccioli, Cindy van Velthoven, Cobi J. Heijnen. 2014. Exosomes: A New Weapon to Treat the Central Nervous System. *Molecular Neurobiology* **49**, 113-119. [[CrossRef](#)]
51. Benjamin D. Humphreys. 2014. Kidney injury, stem cells and regeneration. *Current Opinion in Nephrology and Hypertension* **23**, 25-31. [[CrossRef](#)]
52. Stefano Da Sacco, Laura Perin, Sargis Sedrakyan Renal Regeneration 241-252. [[CrossRef](#)]
53. Lotta Kilpinen, Ulla Impola, Lotta Sankkila, Ilja Ritamo, Maria Aatonen, Sami Kilpinen, Jarno Tuimala, Leena Valmu, Jouko Levijoki, Piet Finckenberg, Pia Siljander, Esko Kankuri, Eero Mervaala, Saara Laitinen. 2013. Extracellular membrane vesicles from umbilical cord blood-derived MSC protect against ischemic acute kidney injury, a feature that is lost after inflammatory conditioning. *Journal of Extracellular Vesicles* **2**. . [[CrossRef](#)]
54. Stefania Bruno, Giovanni Camussi. 2013. Role of mesenchymal stem cell-derived microvesicles in tissue repair. *Pediatric Nephrology* **28**, 2249-2254. [[CrossRef](#)]
55. Serhiy Forostyak, Pavla Jendelova, Eva Sykova. 2013. The role of mesenchymal stromal cells in spinal cord injury, regenerative medicine and possible clinical applications. *Biochimie* **95**, 2257-2270. [[CrossRef](#)]
56. Stefano Pluchino, Chiara Cossetti. 2013. How stem cells speak with host immune cells in inflammatory brain diseases. *Glia* **61**:10.1002/glia.v61.9, 1379-1401. [[CrossRef](#)]
57. Stefania Bruno, Benedetta Bussolati. 2013. Therapeutic effects of mesenchymal stem cells on renal ischemia-reperfusion injury: a matter of genetic transfer?. *Stem Cell Research & Therapy* **4**, 55. [[CrossRef](#)]